Fig. 6: Safety of the BNT162b2-based cancer therapy and the combinational therapy of BNT162b2 and anti-PD-L1.

a Experimental design for investigating the safety of cancer therapeutic strategies in this study. b H&E staining of major organs post different therapeutic strategies. c Body weight changes of treatment and control groups during the experimental period. d Luciferase signals of major organs after a single-dose Luc mRNA-LNP intratumoral injection. e Whole body Luciferase signals after a single-dose Luc mRNA-LNP intratumoral injection. BNT i.m.-PBS i.t.-αIso i.p.: the mice with BNT162b2 intramuscular injections, PBS intratumoral injections, and isotype antibody (αIso) intraperitoneal injections. BNT i.m.-BNT i.t.-αIso i.p.: the mice with BNT162b2 intramuscular injections, BNT162b2 intratumoral injections, and isotype antibody (αIso) intraperitoneal injections. BNT i.m.-PBS i.t.-αPD-L1 i.p.: the mice with BNT162b2 intramuscular injections, PBS intratumoral injections, and anti-PD-L1 antibody intraperitoneal injections. BNT i.m.-BNT i.t.-αPD-L1 i.p.: the mice with BNT162b2 intramuscular injections, BNT162b2 intratumoral injections, and anti-PD-L1 antibody intraperitoneal injections. The time points of different administrations were shown in a. In b, the scale bars represent the following: 700 μm and 50 μm in the first and second lines of the H&E staining of the heart, respectively; 800 μm and 50 μm in the first and second lines of the H&E staining of the liver, respectively; 600 μm and 50 μm in the first and second lines of the H&E staining of the spleen, respectively; 800 μm and 100 μm in the first and second lines of the H&E staining of the lung, respectively; and 600 μm and 50 μm in the first and second lines of the H&E staining of the kidney, respectively.